PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
29458047-0	2018	Effects of cytochrome P450 single nucleotide polymorphisms on methadone metabolism and pharmacodynamics.	Methadone	62-71	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	11-26	
29458047-4	2018	Methadone is primarily metabolized in the liver by cytochrome P450 (CYP) enzymes, predominately by CYP2B6, followed by CYP3A4, 2C19, 2D6, and to a lesser extent, CYP2C18, 3A7, 2C8, 2C9, 3A5, and 1A2.	Methadone	0-9	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	51-66	
29458047-4	2018	Methadone is primarily metabolized in the liver by cytochrome P450 (CYP) enzymes, predominately by CYP2B6, followed by CYP3A4, 2C19, 2D6, and to a lesser extent, CYP2C18, 3A7, 2C8, 2C9, 3A5, and 1A2.	Methadone	0-9	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	68-71	
29458047-4	2018	Methadone is primarily metabolized in the liver by cytochrome P450 (CYP) enzymes, predominately by CYP2B6, followed by CYP3A4, 2C19, 2D6, and to a lesser extent, CYP2C18, 3A7, 2C8, 2C9, 3A5, and 1A2.	Methadone	0-9	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	99-105	
29458047-4	2018	Methadone is primarily metabolized in the liver by cytochrome P450 (CYP) enzymes, predominately by CYP2B6, followed by CYP3A4, 2C19, 2D6, and to a lesser extent, CYP2C18, 3A7, 2C8, 2C9, 3A5, and 1A2.	Methadone	0-9	cytochrome P450 family 2 subfamily C member 18	Homo sapiens	162-169	
29458047-6	2018	Several SNPs in the CYP2B6, 3A4, 2C19, 2D6, and 3A5 genes result in increases in methadone plasma concentrations, decreased N-demethylation, and decreased methadone clearance.	Methadone	81-90	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	20-26	
29458047-6	2018	Several SNPs in the CYP2B6, 3A4, 2C19, 2D6, and 3A5 genes result in increases in methadone plasma concentrations, decreased N-demethylation, and decreased methadone clearance.	Methadone	155-164	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	20-26	
29458047-7	2018	In particular, carriers of CYP2B6*6/*6 may have a greater risk for detrimental adverse effects, as methadone metabolism and clearance are diminished in these individuals.	Methadone	99-108	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	27-33	
29458047-8	2018	CYP2B6*4, on the other hand, has been observed to decrease plasma concentrations of methadone due to increased methadone clearance.	Methadone	84-93	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	0-6	
29458047-8	2018	CYP2B6*4, on the other hand, has been observed to decrease plasma concentrations of methadone due to increased methadone clearance.	Methadone	111-120	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	0-6	
29458047-9	2018	The involvement, contribution, and understanding the role of SNPs in CYP2B6, and other CYP genes, in methadone metabolism can improve the therapeutic uses of methadone in patient outcome and the development of personalized medicine.	Methadone	101-110	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	69-75	
29458047-9	2018	The involvement, contribution, and understanding the role of SNPs in CYP2B6, and other CYP genes, in methadone metabolism can improve the therapeutic uses of methadone in patient outcome and the development of personalized medicine.	Methadone	101-110	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	69-72	
29458047-9	2018	The involvement, contribution, and understanding the role of SNPs in CYP2B6, and other CYP genes, in methadone metabolism can improve the therapeutic uses of methadone in patient outcome and the development of personalized medicine.	Methadone	158-167	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	69-75	
29458047-9	2018	The involvement, contribution, and understanding the role of SNPs in CYP2B6, and other CYP genes, in methadone metabolism can improve the therapeutic uses of methadone in patient outcome and the development of personalized medicine.	Methadone	158-167	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	69-72